CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole

被引:9
作者
Denisenko, Natalia P. [1 ,2 ,3 ]
Sychev, Dmitriy A. [2 ]
Sizova, Zhanna M. [3 ]
Smirnov, Valeriy V. [4 ,5 ]
Ryzhikova, Kristina A. [1 ]
Sozaeva, Zhannet A. [1 ]
Grishina, Elena A. [1 ]
机构
[1] Russian Med Acad Continuous Profess Educ, Minist Healthcare, Res Ctr, Moscow, Russia
[2] Russian Med Acad Continuous Profess Educ, Minist Healthcare, Dept Clin Pharmacol & Therapy, Moscow, Russia
[3] Sechenov Univ, Moscow State Med Univ 1, Minist Healthcare, Dept Social Expertise Urgent & Outpatient Therapy, Moscow, Russia
[4] Sechenov Univ, Moscow State Med Univ 1, Minist Healthcare, Dept Pharmaceut & Toxicol Chem, Moscow, Russia
[5] Fed Med Biol Agcy, Lab Clin Pharmacol, Natl Res Ctr, Inst Immunol, Moscow, Russia
来源
PHARMACOGENOMICS & PERSONALIZED MEDICINE | 2018年 / 11卷
关键词
pharmacogenetics; phenotyping; metabolomics; proton pump inhibitor; EXPRESSION; CYP3A4-ASTERISK-22; PHARMACOKINETICS; IDENTIFICATION; VARIABILITY; VARIANTS; RATIO;
D O I
10.2147/PGPM.S159708
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Proton pump inhibitors (PPIs) are metabolized by cytochrome P450. CYP2C19 is the main isoenzyme for the majority of PPI, whereas CYP3A family is a secondary enzyme for PPI biotransformation. Purpose: The aim of the study was to find if CYP3A4*22, CYP3A5*3, CYP2C19*2, CYP2C19*3, and CYP2C19*17 genotypes are connected with CYP3A and CYP2C19 activities in Russian peptic ulcer patients taking omeprazole. Patients and methods: Forty-eight gastric or duodenal ulcer patients (15 men, 33 women; mean age 55.0 +/- 15.3 years, age range 18-91 years) from Moscow region of Russia were enrolled. Peripheral venous blood was collected for DNA extraction, and real-time polymerase chain reaction was performed for CYP3A5*3(A6986G) (rs776746), CYP3A4*22 C>T in intron 6 (rs35599367), CYP2C19*2(G681A) (rs4244285), CYP2C19*3(G636A) (rs4986893), and CYP2C19*17(C-806T) (rs12248560) polymorphism analyses. Urine samples of patients were collected in the morning between 6 and 9 am before food or drug intake. Urine cortisol and 6 beta-hydroxycortisol concentrations (for CYP3A activity) and omeprazole and 5-hydroxyomeprazole concentrations (for CYP2C19 activity) were measured using high-performance liquid chromatography/mass spectroscopy. Results: We found a connection between CYP2C19 genotypes and CYP3A activity. Median metabolic ratios 6 beta-hydroxycortisol/cortisol (25%-75% percentiles) were 2.84 (1.99-4.39) for CYP2C19 extensive metabolizers (EMs), 2.51 (1.86-4.73) for CYP2C19 ultra-rapid metabolizers (UMs), and 1.45 (1.12-2.16) for CYP2C19 intermediate metabolizers (IMs) + poor metabolizers (PMs). A statistically significant difference in CYP3A activity (Mann-Whitney test) was found between CYP2C19 EMs vs CYP2C19 IMs+PMs (p=0.006), between CYP2C19 UMs vs CYP2C19 IMs+PMs (p=0.018), and in multiple comparison Kruskal-Wallis test (p=0.014). Conclusion: In CYP2C19 IMs+PMs, CYP3A activity was significantly lower than in CYP2C19 EMs and UMs.
引用
收藏
页码:107 / 112
页数:6
相关论文
共 24 条
[1]  
Dai D, 2001, J PHARMACOL EXP THER, V299, P825
[2]   Significance of the minor cytochrome P450 3A isoforms [J].
Daly, AK .
CLINICAL PHARMACOKINETICS, 2006, 45 (01) :13-31
[3]   Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients [J].
Denisenko, Natalia P. ;
Sychev, Dmitriy A. ;
Sizova, Zhanna M. ;
Smirnov, Valeriy V. ;
Ryzhikova, Kristina A. ;
Sozaeva, Zhannet A. ;
Grishina, Elena A. .
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2017, 10 :253-259
[4]   Identification and functional characterization of eight CYP3A4 protein variants [J].
Eiselt, R ;
Domanski, TL ;
Zibat, A ;
Mueller, R ;
Presecan-Siedel, E ;
Hustert, E ;
Zanger, UM ;
Brockmoller, J ;
Klenk, HP ;
Meyer, UA ;
Khan, KK ;
He, YA ;
Halpert, JR ;
Wojnowski, L .
PHARMACOGENETICS, 2001, 11 (05) :447-458
[5]  
Elens L, 2013, PHARMACOGENOMICS, V14, P47, DOI [10.2217/PGS.12.187, 10.2217/pgs.12.187]
[6]   The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients [J].
Elens, Laure ;
Bouamar, Rachida ;
Hesselink, Dennis A. ;
Haufroid, Vincent ;
van Gelder, Teun ;
van Schaik, Ron H. N. .
PHARMACOGENETICS AND GENOMICS, 2012, 22 (05) :373-380
[7]   Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study [J].
Elens, Laure ;
Becker, Matthijs L. ;
Haufroid, Vincent ;
Hofman, Albert ;
Visser, Loes E. ;
Uitterlinden, Andre G. ;
Stricker, Bruno Ch ;
van Schaik, Ron H. N. .
PHARMACOGENETICS AND GENOMICS, 2011, 21 (12) :861-866
[8]   A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients [J].
Elens, Laure ;
Bouamar, Rachida ;
Hesselink, Dennis A. ;
Haufroid, Vincent ;
van der Heiden, Ilse P. ;
van Gelder, Teun ;
van Schaik, Ron H. N. .
CLINICAL CHEMISTRY, 2011, 57 (11) :1574-1583
[9]   Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA [J].
Koch, I ;
Weil, R ;
Wolbold, R ;
Brockmöller, J ;
Hustert, E ;
Burk, O ;
Neussler, A ;
Neuhaus, P ;
Eichelbaum, M ;
Zanger, U ;
Wojnowski, L .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (10) :1108-1114
[10]   Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression [J].
Kuehl, P ;
Zhang, J ;
Lin, Y ;
Lamba, J ;
Assem, M ;
Schuetz, J ;
Watkins, PB ;
Daly, A ;
Wrighton, SA ;
Hall, SD ;
Maurel, P ;
Relling, M ;
Brimer, C ;
Yasuda, K ;
Venkataramanan, R ;
Strom, S ;
Thummel, K ;
Boguski, MS ;
Schuetz, E .
NATURE GENETICS, 2001, 27 (04) :383-391